Joa_Souza Investment Thesis I recommend buying Braskem (NYSE:BAK) shares after the release of 2Q24 results, which, although below market expectations, showed good signs of operational improvement for the company. Although the company still has problems with financial expenses and net losses, Braskem achieved excellent cost control in 2Q24, which combined with a 33% appreciation potential makes me confident in the thesis. Review Of Braskem's 2Q24 Results Braskem released its 2nd quarter results on August 8th ...